TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged \> 18~* Histologically confirmed epithelial ovarian, peritoneal, or fallopian tube cancer, and uterine papillary serous carcinomas (UPSC), and gynecologic malignant mixed müllerian tumors (MMMTs).~* Must have had prior platinum or platinum based therapy.~* Eastern Cooperative Oncology Group (ECOG) status 0-1.~* Platinum resistant or refractory disease within 6 months of completing or while receiving a platinum and taxane containing regimen~* Measurable disease~* Adequate bone marrow and hematological function.~* Must have recovered from acute toxicity from prior treatment~* Prior treatment with an anti-angiogenic agent is not an exclusion criterion.~* No prior GI perforation, or GI obstruction or involvement of the bowel on imaging~* Known hypersensitivity to Cremophor EL. However, participants are eligible if they have had a prior paclitaxel reaction, but subsequently tolerated the drug at rechallenge.~* No patients receiving other investigational therapy for the past 30 days before dosing.~Exclusion Criteria:~* More than 3 prior lines of chemotherapy for recurrent cancer.~* History of other active malignancy, other than superficial basal cell and superficial squamous cell, or carcinoma in situ of the cervix within last 2 years.~* Life expectancy of less than 3 months~* CTC Grade 1 or greater neuropathy (motor or sensory) from comorbidity other than prior taxane exposure, such as diabetes.~* Inadequately controlled hypertension or prior history of hypertensive crisis or hypertensive encephalopathy.~* New York Heart Association (NYHA) Grade II or greater congestive heart failure.~* History of myocardial infarction or unstable angina within 6 months prior to study Day 1.~* History of stroke or transient ischemic attack within 6 months prior to Day 1.~* Known CNS disease, except for treated brain metastasis~* Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1.~* History of hemoptysis (1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1.~* Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VB-111 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telmisartan, Amlodipine and Combination in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~1. Healthy males and females~2. Aged between 18 and 45 years~3. Body weight more than 50Kg , and Body Mass Index (BMI ) between 19 and 24 kg/m2~Exclusion criteria~1. Any finding of the medical examination deviating from normal and of clinical relevance~2. Any evidence of a clinically relevant concomitant disease~3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders~4. Surgery of the gastrointestinal tract (except appendectomy)~5. Diseases of the central nervous system or psychiatric disorders or neurological disorders~6. History of relevant orthostatic hypotension, fainting spells or blackouts.~7. Chronic or relevant acute infections~8. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)~9. Intake of drugs with a long half-life (\> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial~10. Use of drugs which might reasonably influence the results of the trial~11. Participation in another trial with an investigational drug within two months prior to administration or during the trial~12. Smoker~13. Inability to refrain from smoking during 24 hours prior to dosing and during the trial~14. Alcohol abuse or inability to stop alcoholic beverages for 24 hours prior to dosing and during the trial~15. Drug abuse~16. Blood donation (more than 100 mL within four weeks prior to administration or during the trial)~17. Excessive physical activities (within one week prior to administration or during the trial)~18. Any laboratory value outside the reference range that is of clinical relevance~19. Inability to comply with dietary regimen of trial site~20. A history of additional risk factors for torsade de pointes~21. Any history of relevant low blood pressure~22. Supine blood pressure at screening of systolic \<110 mm Hg and diastolic \< 60 mm Hg~23. History of urticaria~24. History of angioneurotic edema 25 Pregnancy / positive pregnancy test, or planning to become pregnant during the study or within 1 month of study completion~26. No adequate contraception during the study and until 1 month of study completion 27. Lactation period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- amlodipine/telmisartan/combination (Type: EXPERIMENTAL): all patients will be assigned to 6 treatment sequences. cross-over design was adopted to ensure each patient would take amlodipine/telmisartan/combination single dose in randomized order

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial Comparing Effectiveness of Buffered Versus Unbuffered Local Anesthetic in Children Ages 10-12 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 10-12 years~* American Society of Anesthesiologists (ASA) Class I (Healthy)~* Body Weight: the Interquartile Range (IQR) 33-60Kg for subject ages~* Have ability to speak and read English~* Willingness to participate in two sessions~* No history of adverse reaction to dental anesthetic~* Have bilateral, disease/symptom-free mandibular first molars present~Exclusion Criteria:~* Allergy to lidocaine class of anesthetic drugs~* Local anesthetic drug use in past week~* Current symptomatic teeth or oral mucosa~* ASA II or above (including asthma)

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Buffered Anesthetic, then Unbuffered Anesthetic (Type: EXPERIMENTAL): Subjects randomized to Buffered Anesthetic, then Unbuffered Anesthetic will first receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine.
- Unbuffered Anesthetic, then Buffered Anesthetic (Type: EXPERIMENTAL): Subjects randomized to Unbuffered Anesthetic, then Buffered Anesthetic will first receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with single-level LDH (L4-L5 or L5-S1 (or L5-L6)) with clear, demonstrable nerve root impingement as assessed by magnetic resonance imaging (MRI) and clinical symptoms corresponding to position of the impaired nerve root.~* Subjects with radiculopathy/radicular leg pain in the unilateral leg for 6 weeks or more but 1 year or less.~* Subjects with positive result of Straight Leg Raise (SLR) test (≤70°) only on the ipsilateral leg having chief complaint of radiculopathy~* Subjects with inadequate improvement in pain caused by LDH despite 6 weeks or more of conservative treatment.~Exclusion Criteria:~* Subjects who have 2 or more lumbar disc herniations as assessed by MRI.~* Subjects who have undergone a lumbar operation, lumbar percutaneous nucleotomy, or lumbar intradiscal therapies at the affected level of lumbar spine.~* Subjects who have received block procedure (e.g., spinal injection, epidural injection or nerve block) for treatment of LDH, oral or injectable corticosteroids within 28 days prior to randomization.~* Subjects who have received opioids or cannabis by any route of administration, local anesthesia to the back, buttock, or posterior/lateral aspects of the affected leg within 7 days prior to randomization.~* Subjects with a body mass index (BMI) ≥40.~* Subjects who are receiving compensation according to the Workers' Compensation Act or are involved in personal injury litigation due to a lumbar-related injury.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SI-6603 (Type: EXPERIMENTAL): None
- Sham injection (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Patients with (any one of #1, #2, and/or #3):~  1. Suspicion of neuroendocrine tumors (NET) on axial imaging (computed tomography (CT)/magnetic resonance imaging (MRI)/fluorodeoxyglucose (FDG) positron emission tomography (PET) and/or~ 2. biochemical evidence of neuroendocrine tumor (serum/urinary) based on elevated levels of chromogranin A, pancreatic polypeptide, neuron-specific enolase, vasoactive intestinal polypeptide, serotonin (urinary 5-HIAA), gastrin, somatostatin, catecholamines, metanephrines, calcitonin, fasting insulin, C-peptide (proinsulin), glucagon and/or~ 3. familial predisposition to NET in patients with multiple endocrine neoplasia type 1 (MEN1) and Von Hippel-Lindau (VHL) (symptomatic and/or asymptomatic cases; with biochemical or anatomic imaging evidence of disease).~* Age greater than or equal to 10 years of age.~* For females: Negative urine pregnancy test OR post-menopausal for at least 2 years OR patient has had a hysterectomy.~* Patients must be willing to return to National Institutes of Health (NIH) for follow-up.~* Ability of subject or Legally Authorized Representative (LAR) (if the patient is deemed by the treating physician to be cognitively impaired or questionably impaired in such a way that the ability of the patient to give informed consent is questionable) to understand and the willingness to sign a written informed consent document indicating that they are aware of the investigational nature of this study.~EXCLUSION CRITERIA:~* Patients unwilling to undergo serial non-invasive imaging.~* Pregnant or lactating women: Pregnant women are excluded from this study because the effects of (68)Ga-DOTATATE in pregnancy are not known. Because there is an unknown but potential risk for adverse events in nursing infants secondary to administration of~  (68)Ga-DOTATATE in the mother, breastfeeding should be discontinued for at least one day if the mother receives (68)Ga-DOTATATE.~* Patients that have recognized concurrent active infection,~* Patients with the use of any investigational product or device, excluding 18F-dihydroxyphenylalanine (F-DOPA) scans, within 30 days prior to dosing.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 68Gallium DOTATATE imaging (Type: EXPERIMENTAL): 68Gallium DOTATATE imaging

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Magnesium Sulphate Infusion on Lung Mechanics and Oxygenation in COPD Patients Undergoing Total Laryngeal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing cancer larynx surgery (partial laryngectomy, total laryngectomy with or without neck dissection).~* Age more than 40 years old~* ASA physical status II and III.~* Diagnosed as having COPD by preoperative spirometry. The classification is bases on the post-bronchodilators forced expiratory volume in the first second (FEV1). Mild COPD is diagnosed when FEV1 is \> 80% of predicted while moderate COPD is diagnosed when FEV1 is \< 80% and \> 50% of predicted and sever COPD is diagnosed when FEV1 is \< 50% and \> 30% of predicted~Exclusion Criteria:~* o Patients with heart failure.~  * History with arrhythmias or treatment with antiarrhythmic drugs.~ * Patient with heart block or on beta blockers or calcium channel blockers.~ * Patients with impaired renal function (creatinine \> 2)~ * Patients with impaired liver function (ALT more than 2 folds).~ * Patient with combined restrictive and obstructive pulmonary disease.~ * Patients with preoperative tracheostomy.~ * Patients with huge mass obstructing \> 50% of the view. (due to its influence on the spirometry measurements).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Mg-group (Type: EXPERIMENTAL): 10% MgSO4 solution will be used, a loading dose of 30mg/kg over 20 min (equivalent to infusion rate of 0.9 ml/kg/hr for 20 min) will be given followed by continuous infusion of 10mg/kg/hr (equivalent to infusion rate of 0.1ml/kg/hr).
- Control group (Type: NO_INTERVENTION): In control group, same rates of infusion for loading and maintenance will be applied using 0.9 normal saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CP1110 Sound Processor Feasibility

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 18 years or older~2. Post lingually deafened~3. Implanted with the CI600 Series (CI612, CI632, CI622, CI624), CI500 Series (CI512, CI532, CI522) or Freedom Series (CI24RE(CA), CI24RE(ST), CI422)~4. At least 6 months experience with a cochlear implant.~5. At least 3 months experience with a Nucleus 6 (CP910/920), Kanso (CP950), Kanso 2 (CP1150) or Nucleus 7 (CP1000) Sound Processor~6. Able to score 30% or more at +15 SNR with CI alone on a sentence in babble test~7. Willingness to participate in and to comply with all requirements of the protocol.~8. Fluent speaker in English as determined by the investigator~9. Willing and able to provide written informed consent~Exclusion Criteria:~1. Additional disabilities that would prevent participation in evaluations.~2. Unrealistic expectations on the part of the subject, regarding the possible benefits, risks and limitations that are inherent to the procedures.~3. Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator.~4. Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling.~5. Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation.~6. Currently participating, or participated in another interventional clinical study/trial in the past 30 days, or (if less than 30 days) the prior investigation was Cochlear sponsored and determined by the investigator to not impact clinical findings of this investigation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- CP1000 Sound Processor followed by the CP1110 Sound Processor (Type: EXPERIMENTAL): All study subjects were provided with a unique identifier. The ones that ended in an odd number were administered the CP1000 Sound Processor followed by the CP1110 Sound Processor.
- CP1110 Sound Processor followed by the CP1000 Sound Processor (Type: EXPERIMENTAL): All study subjects were provided with a unique identifier. The ones that ended in an even number were administered the CP1110 Sound Processor followed by the CP1000 Sound Processor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~- Patients with type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year at the time of the screening visit insufficiently controlled with basal insulin± metformin.~Exclusion criteria:~At screening:~* Age \< legal age of adulthood.~* HbA1c\<7% or \>10.5%.~* Basal insulin treatment has not been at a stable regimen for at least 3 months and at a stable dose (± 20%) of at least 15 U/day for at least 2 months prior to screening visit.~* If metformin is given, metformin treatment has not been at a stable dose of at least 1.0 g/day for at least 3 months prior to screening visit.~* History of hypoglycemia unawareness.~* Body Mass Index (BMI) ≤20 kg/m².~* Use of other oral or injectable glucose-lowering agents other than basal insulin or metformin within 3 months prior to the time of screening.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lixisenatide (Type: EXPERIMENTAL): 24-week treatment with lixisenatide once daily on top of basal insulin with or without metformin (at least 1.0g/day)
- Placebo (Type: PLACEBO_COMPARATOR): 24-week treatment with placebo once daily on top of basal insulin with or without metformin (at least 1.0g/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Mindfulness-based Intervention for Older Women With Low Sexual Desire

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* meet criteria for a diagnosis of Female Sexual Interest/Arousal Disorder~* English-speaking~* have a current sexual partner with whom they are or would like to be sexually active~Exclusion Criteria:~* active major depression~* active substance abuse~* current intimate partner violence~* partner with active major depression~* partner with active major substance abuse~* significant relationship dissatisfaction~* current use of antidepressants~* untreated dyspareunia (sexual pain)

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mindfulness group (Type: EXPERIMENTAL): A multicomponent group-based intervention rooted in mindfulness, administered in 3 sessions over 6 weeks
- educational group (Type: ACTIVE_COMPARATOR): A general midlife health and aging educational group, administered in 3 sessions over 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Recurrent epithelial ovarian or fallopian tube or peritoneal serous carcinomas with measurable disease as assessed by Response Evaluation Criteria in Solid Tumors criteria~* Patients will require to have received a platinum-containing regimen as primary treatment and at least one line of chemotherapy for recurrent disease~* An interval time from the last platinum-based chemotherapy after 6months~* 18 years of years~* Eastern Cooperative Oncology Group performance status of 0 to 2~* Adequate bone marrow~* Adequate renal and hepatic functions~* Written informed consent to the study protocol~Exclusion Criteria:~* Hypersensitivity to celecoxib or aspirin or other nonsteroidal anti-inflammatory drugs or sulfonamides~* Significant comorbidities including any active coronary artery disease requiring management or symptomatic congestive heart failure or bleeding diathesis or uncontrolled severe hypertension or active gastrointestinal ulcer within 12 months or chronic inflammatory bowel diseases or deep venous or arterial thrombosis within 12 months or history of pulmonary embolism~* Concomitant use of possible interactive drugs~* Surgery and chemotherapy or radiotherapy within 1 month~* Actual or potential childbearing~* Breast-feeding~* Prior cancer treatment with a COX2 inhibitor~* Any psychological and/or sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete